CYTK

SEC source: 0001061983-21-000002 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-21-000002 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,589

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,991 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-21-000002 · edgardoc.xml · nonDerivative · entry 1

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,991 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-21-000018 · edgardoc.xml · nonDerivative · entry 1

Wysenski Nancy · CIK 0001294596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 255 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-21-000016 · edgardoc.xml · nonDerivative · entry 1

SMITH SANDFORD D · CIK 0001243004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 511

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-21-000017 · edgardoc.xml · nonDerivative · entry 1

WIERENGA WENDALL · CIK 0001235945 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 511

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-21-000014 · edgardoc.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,410

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-21-000015 · edgardoc.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 511

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-21-000013 · edgardoc.xml · nonDerivative · entry 1

GAGE L PATRICK · CIK 0001196903 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,762

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 958 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-21-000012 · edgardoc.xml · nonDerivative · entry 1

Califf Robert · CIK 0001574557 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255

F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021.

F2 · balance_after: Amount includes 255 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.

SEC source: 0001061983-20-000193 · edgardoc.xml · derivative · entry 4

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 858 shares

Expires 2021-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020.

SEC source: 0001061983-20-000193 · edgardoc.xml · nonDerivative · entry 2

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 899

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020.

SEC source: 0001061983-20-000193 · edgardoc.xml · nonDerivative · entry 1

HENDERSON JOHN T · CIK 0001226488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,757

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 3, 2020.

SEC source: 0001061983-20-000191 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-20-000191 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,589

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,991 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000191 · edgardoc.xml · nonDerivative · entry 1

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,991 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000187 · edgardoc.xml · derivative · entry 4

GAGE L PATRICK · CIK 0001196903 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,716 shares

Expires 2021-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-20-000187 · edgardoc.xml · nonDerivative · entry 2

GAGE L PATRICK · CIK 0001196903 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,804

SEC source: 0001061983-20-000187 · edgardoc.xml · nonDerivative · entry 1

GAGE L PATRICK · CIK 0001196903 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 8

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,243 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 7

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,243

Underlying: Common Stock · 7,423 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 6

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,666

Underlying: Common Stock · 7,423 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Incentive stock options granted on 2/28/2011 to purchase 7,423 shares at an exercise price of $9.42 per share converted to non-qualified stock options to purchase 7,423 shares at an exercise price of $9.42 per share as a result of a modification to the original grant to permit a "net exercise" of the stock options. Conversion transaction is permitted pursuant to the Issuer's Amended and Restated 2004 Equity Incentive Plan and the prior resolution of the Issuer's Compensation and Talent Committee of the Board of Directors.

SEC source: 0001061983-20-000189 · edgardoc.xml · derivative · entry 5

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 7,423 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Incentive stock options granted on 2/28/2011 to purchase 7,423 shares at an exercise price of $9.42 per share converted to non-qualified stock options to purchase 7,423 shares at an exercise price of $9.42 per share as a result of a modification to the original grant to permit a "net exercise" of the stock options. Conversion transaction is permitted pursuant to the Issuer's Amended and Restated 2004 Equity Incentive Plan and the prior resolution of the Issuer's Compensation and Talent Committee of the Board of Directors.

F4 · balance_after: Number of derivative securities beneficially owned following reported transaction is zero (0). The 1 security that is reported is the result of rounding of shares attributable to Issuer?s reverse stock split that occurred on 6/25/2013.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 4

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,229

F2 · kind: Transaction represents a "net exercise" of 9,243 outstanding non-qualified stock options granted on 2/28/2011 and 7,423 outstanding non-qualified stock options that result from the conversion on 12/15/20 of incentive stock options granted on 2/28/2011. The Reporting Person received 6,013 shares of Common Stock on the net exercise of a stock options to purchase an aggregate of 16,666 shares of Common Stock, with a remaining payable by Reporting Person to the Issuer of $17.45. The Issuer withheld 10,653 shares of Common Stock underlying the stock options for payment of the exercise price and tax withholding using a stock price on 12/15/20 of $21.00. In addition to the withholding of 10,653 shares of Common Stock, the Reporting Person will pay $17.45 in cash to the Issuer for the remainder of his exercise price and tax liability.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 3

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 2

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,894

F2 · kind: Transaction represents a "net exercise" of 9,243 outstanding non-qualified stock options granted on 2/28/2011 and 7,423 outstanding non-qualified stock options that result from the conversion on 12/15/20 of incentive stock options granted on 2/28/2011. The Reporting Person received 6,013 shares of Common Stock on the net exercise of a stock options to purchase an aggregate of 16,666 shares of Common Stock, with a remaining payable by Reporting Person to the Issuer of $17.45. The Issuer withheld 10,653 shares of Common Stock underlying the stock options for payment of the exercise price and tax withholding using a stock price on 12/15/20 of $21.00. In addition to the withholding of 10,653 shares of Common Stock, the Reporting Person will pay $17.45 in cash to the Issuer for the remainder of his exercise price and tax liability.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000189 · edgardoc.xml · nonDerivative · entry 1

Cragg David · CIK 0001316459 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,639

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

SEC source: 0001061983-20-000185 · edgardoc.xml · nonDerivative · entry 1

Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,441

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0000921895-20-003224 · form407422cytk_12112020.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanaton of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 463,244

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-20-003224 · form407422cytk_12112020.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanaton of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,760,185

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-20-003224 · form407422cytk_12112020.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanaton of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,811,271

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001061983-20-000183 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-20-000183 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,589

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,991 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000183 · edgardoc.xml · nonDerivative · entry 1

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,991 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000181 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-20-000181 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,868

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000181 · edgardoc.xml · nonDerivative · entry 1

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0000921895-20-003087 · form407422cytk_11202020.xml · derivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanaton of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value · 9,300 shares

Expires 2020-11-20

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · derivative.exercise_date: Represents unexercised and out-of-the money call options (with 100 multiplier), which expired on November 20, 2020. The call options had an exercise price of $20.00.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-20-003087 · form407422cytk_11202020.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanaton of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value · 55,100 shares

Expires 2020-11-20

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · derivative.exercise_date: Represents unexercised and out-of-the money call options (with 100 multiplier), which expired on November 20, 2020. The call options had an exercise price of $20.00.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-20-003087 · form407422cytk_11202020.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanaton of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value · 74,000 shares

Expires 2020-11-20

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · derivative.exercise_date: Represents unexercised and out-of-the money call options (with 100 multiplier), which expired on November 20, 2020. The call options had an exercise price of $20.00.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001061983-20-000179 · edgardoc.xml · derivative · entry 1

Wysenski Nancy · CIK 0001294596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2030-11-20

F1 · derivative.exercise_date: This option shall vest and become exercisable as to 35,000 shares divided into equal monthly installments with the first vesting installment on December 20, 2020 and the final vesting installment on November 20, 2023.

SEC source: 0001061983-20-000177 · edgardoc.xml · nonDerivative · entry 1

Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,951

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 1,980 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000175 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-20-000175 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,868

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000175 · edgardoc.xml · nonDerivative · entry 1

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000173 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-20-000173 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,868

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000173 · edgardoc.xml · nonDerivative · entry 1

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).

SEC source: 0001061983-20-000171 · edgardoc.xml · derivative · entry 5

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,434

Underlying: Common Stock · 5,000 shares

Expires 2023-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

SEC source: 0001061983-20-000171 · edgardoc.xml · nonDerivative · entry 2

Blum Robert I · CIK 0001288859 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,868

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020.

F2 · balance_after: Includes 4,270 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP).